{"filing":{"accession_number":"0000875045-26-000068","cik":"0000875045","ticker":"BIIB","company_name":"BIOGEN INC.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"biib-20260701.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/biib-20260701.htm"},"events":[{"id":15483,"run_id":13811,"accession_number":"0000875045-26-000068","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Biogen discloses preliminary unaudited financial results for Q2 2026 and provides guidance for Q3 2026, including specific charges ($164M for Q2, $290-320M for Q3) and their impact on GAAP and non-GAAP earnings per share ($0.95 and $1.75-1.95 respectively). While the disclosure focuses on acquired in-process R\u0026D and milestone expenses rather than comprehensive earnings, it constitutes a material financial results disclosure under Item 2.02 that would affect investor assessment of quarterly performance.","company_name":"BIOGEN INC.","ticker":"BIIB","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13275,"accession_number":"0000875045-26-000068","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Biogen discloses preliminary unaudited financial results for Q2 2026 and provides guidance for Q3 2026, including specific charges ($164M for Q2, $290-320M for Q3) and their impact on GAAP and non-GAAP earnings per share ($0.95 and $1.75-1.95 respectively). While the disclosure focuses on acquired in-process R\u0026D and milestone expenses rather than comprehensive earnings, it constitutes a material financial results disclosure under Item 2.02 that would affect investor assessment of quarterly performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:12:49.110482+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13275,"accession_number":"0000875045-26-000068","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Biogen discloses preliminary unaudited financial results for Q2 2026 and provides guidance for Q3 2026, including specific charges ($164M for Q2, $290-320M for Q3) and their impact on GAAP and non-GAAP earnings per share ($0.95 and $1.75-1.95 respectively). While the disclosure focuses on acquired in-process R\u0026D and milestone expenses rather than comprehensive earnings, it constitutes a material financial results disclosure under Item 2.02 that would affect investor assessment of quarterly performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:12:49.110482+00:00","company_name":"BIOGEN INC.","ticker":"BIIB","filing_date":"2026-07-01"}]}